ALIMTA helped keep most common form of lung cancer at bay in elderly patients
26 September 2011 | By Eli Lilly and Company
New data from PARAMOUNT study shows benefit in this hard-to-treat population...
List view / Grid view
26 September 2011 | By Eli Lilly and Company
New data from PARAMOUNT study shows benefit in this hard-to-treat population...
26 September 2011 | By Novartis
Afinitor® more than doubled the time women lived without tumor growth...
26 September 2011 | By Eli Lilly and Company
CHMP has issued a positive opinion for the use of ALIMTA® as continuation maintenance therapy for deadly form of lung cancer...
26 September 2011 | By AstraZeneca
AstraZeneca announced that FASLODEX™ (fulvestrant) has received regulatory approval...
25 September 2011 | By Roche
Phase II study TDM4450g results announced...
23 September 2011 | By AstraZeneca
KOMBOGLYZE™ receives a positive opinion from CHMP...
23 September 2011 | By Novartis
The CHMP adopted a positive opinion for Rasitrio® for the treatment of high blood pressure...
23 September 2011 | By Novartis
A Phase III study of Afinitor® (everolimus) tablets* met its primary endpoint of best overall angiomyolipoma response rate...
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir®...
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir...
22 September 2011 | By Boehringer Ingelheim
Phase II clinical trial results...
21 September 2011 | By Sygnature Discovery Limited
Sygnature Chemical Services, has become Sygnature Discovery to better reflect its Integrated Drug Discovery Service-Offering...
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
21 September 2011 | By Sanofi Pasteur
The pre-clinical vaccine was developed by researchers at the University of California...